Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab

Journal of Dermatological Treatment

Volumn 22, Issue 5, 2011, Pages 261-265

  Kleinpenning, Marloes M ^a   Langewouters, Annechien M G ^a   Van De Kerkhof, Peter C M ^a   Greebe, Rens J ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

Adalimumab; Anti TNF therapy; Biologicals; Etanercept; Pyoderma gangrenosum

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; ETANERCEPT; IMMUNOGLOBULIN; MINOCYCLINE; PREDNISONE;

AGED; ANTIBIOTIC THERAPY; ARTICLE; BURNING SENSATION; CASE REPORT; CLINICAL EFFECTIVENESS; CORTICOSTEROID THERAPY; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; OFF LABEL DRUG USE; OSTEOPOROSIS; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; RELAPSE; SKIN BIOPSY; SKIN ULCER; TREATMENT FAILURE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; WOUND DRESSING;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; PREDNISONE; PYODERMA GANGRENOSUM; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT FAILURE;

EID: 79953104416     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546631003797106     Document Type: Article

References (15)

1. Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB Jr, White WL, Callen JP. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore). 2000;79:37-46. (Pubitemid 30077735)
2. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ. 2006;333:181-184. (Pubitemid 44406745)
3. Nijenhuis T, Klasen I, Weemaes CM, Preijers F, de Vries E, van der Meer JW. Common variable immunodeficiency (CVID) in a family: an autosomal dominant mode of inheritance. Neth J Med. 2001;59:134-139. (Pubitemid 32907201)
4. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther. 2008;117:244-279.
5. Graves JE, Nunley K, Heffernan MP. Off-label uses of bio-logics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol. 2007;56:e55-e79. (Pubitemid 44969298)
6. Pomerantz RG, Husni ME, Mody E, Qureshi AA. Adalimu-mab for treatment of pyoderma gangrenosum. Br J Dermatol. 2007;157:1274-1275.
7. Rogge FJ, Pacifico M, Kang N. Treatment of pyoderma gangrenosum with the anti-TNFalpha drug-etanercept. J Plast Reconstr Aesthet Surg. 2008;61:431-433. (Pubitemid 351389367)
8. Jacobi A, Mahler V, Schuler G, Hertl M. Treatment of inflammatory dermatoses by tumour necrosis factor antagonists. J Eur Acad Dermatol Venereol. 2006;20:1171-1187. (Pubitemid 44614611)
9. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and eta-nercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131(2):308-316.
10. Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009;45: 124-131.
11. Charles CA, Leon A, Banta MR, Kirsner RS. Etanercept for the treatment of refractory pyoderma gangrenosum: A brief series. Int J Dermatol. 2007;46:1095-1099. (Pubitemid 47506384)
12. Disla E, Quayum B, Cuppari GG, Pancorbo R. Successful use of etanercept in a patient with pyoderma gangrenosum complicating rheumatoid arthritis. J Clin Rheumatol. 2004;10:50-52. (Pubitemid 38197536)
13. Pastor N, Betlloch I, Pascual JC, Blanes M, Bañuls J, Silvestre JF. Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept). Clin Exp Dermatol. 2006;31:152-153.
14. Lecluse LL, Driessen RJ, Spuls PI, de Jong EM, Stapel SO, van Doorn MB, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010;146: 127-132.
15. Bartlett BL, Tyring SK. Ustekinumab for chronic plaque psoriasis. Lancet. 2008;371:1639-1640. (Pubitemid 351671871)